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Abstract
Hodgkin lymphoma (HL) is derived from preapoptotic germinal center B cells, although a general loss of B cell
phenotype is noted. Using quantitative reverse transcription–polymerase chain reaction and miRNA microarray,
we determined the microRNA (miRNA) profile of HL and compared this with the profile of a panel of B-cell
non–Hodgkin lymphomas. The two methods showed a strong correlation for the detection of miRNA expression
levels. The HL-specific miRNA included miR-17-92 cluster members, miR-16, miR-21, miR-24, and miR-155. Using
a large panel of cell lines, we found differential expression between HL and other B-cell lymphoma–derived cell
lines for 27 miRNA. A significant down-regulation in HL compared to non–Hodgkin lymphoma was observed only
for miR-150. Next, we performed target gene validation of predicted target genes for miR-155, which is highly
expressed in HL and is differentially expressed between HL and Burkitt lymphoma. Using luciferase reporter
assays, we validated 11 predicted miR-155 target genes in three different HL cell lines. We demonstrated that
AGTR1, FGF7, ZNF537, ZIC3, and IKBKE are true miR-155 target genes in HL.
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Introduction
Hodgkin lymphoma (HL) is one of the most frequently occurring
lymphomas, with an annual incidence rate of three to four new cases
per 100,000 persons in the Western world. Two different subtypes
of HL, i.e., classic (cHL) and nodular lymphocyte predominant
(NLPHL), can be distinguished based on histology, infiltrating cells
and tumor cell characteristics [1]. Classic HL is characterized by the
appearance of Hodgkin and Reed-Sternberg (HRS) cells. These large
multinuclear cells are derived from preapoptotic germinal center
(GC) B cells and are characterized by a loss of B-cell phenotype
[2]. The tumor cells of NLPHL, called lymphocytic and histiocytic
cells, display a relatively normal B-cell phenotype and are also derived
from GC B cells [3]. Using gene expression analysis, an overlap has
been identified between cHL and primary mediastinal B-cell lym-
phoma (PMBL) [4]. Gene expression profiling of B-cell lymphoma
cell lines classified cHL cell lines as a distinct entity, irrespective of
cellular origin, indicating that a specific gene expression program is
activated in cHL [2].
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B-cell–derived lymphoblastoid cell line; CLL, chronic lymphocytic leukemia; DLBCL,
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MicroRNA (miRNA) are short (approximately 22 nt) noncoding
RNA molecules that inhibit gene expression by binding to comple-
mentary sequence at the 3′ untranslated region (UTR) of (target)
genes, including oncogenes and tumor suppressor genes [5]. Nucleo-
tides 2 to 7 from the 5′ end of the miRNA, the seed region, are
considered crucial for miRNA–target gene interaction [6]. MiRNA
expression has been shown to be tissue-specific as well as temporally
regulated [7]. Furthermore, expression of specific miRNA can in-
fluence B-cell [8] and hematopoietic lineage differentiation [9] and
also regulate the GC reaction [10]. Previously, we have shown that
BIC and its mature miRNA product miR-155 are highly expressed in
HL, PMBL, and diffuse large B-cell lymphoma cell lines (DLBCL)
[11,12]. In contrast, Burkitt lymphoma (BL) is characterized by rela-
tively low miR-155 expression levels, indicating a differential regula-
tion of miR-155 expression between these B-cell lymphomas [13].
Germinal center B cells upregulate BIC/miR-155 [10] leading to
down-regulation of target mRNA such as the activation-induced cyti-
dine deaminase [14].
In this study, we established an HL-specific miRNA expression
profile using stem-loop–specific quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) [15] and a miRNA microarray
using the Agilent platform [16]. The specificity of miRNA that were
abundantly or differentially expressed in HL was evaluated in cell lines
derived from various B-cell non–Hodgkin lymphomas. In addition, we
validated 11 predicted target genes of miR-155 in HL cell lines.
Materials and Methods
Cell Lines Included for Profiling of miRNA
The cHL cell lines (L428, KM-H2, and L1236), the NLPHL cell
line (DEV), the EBV-transformed GC B-cell–derived lymphoblastoid
cell lines (CB-LCL 5.B8 and CB-LCL 6.28 [17]), the PMBL cell lines
(Karpas 1106P and MEDB-1), and the EBV-negative BL cell lines
(Ramos, CA46, and DG-75) were cultured at 37°C in an atmosphere
containing 5% CO2 in RPMI-1640 medium (Cambrex Biosciences,
Walkersville, MD) supplemented with penicillin (100 U/ml), strep-
tomycin (0.1 mg/ml), and ultraglutamine (2 mM; Cambrex Bio-
sciences) and 5% (L428), 20% (DEV), or 10% (rest) fetal calf serum
(Cambrex Biosciences). All cell lines included for subsequent qRT-PCR
validation to determine which miRNA are HL-specific are listed in
Table W1.
RNA Isolation
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. The quantity was measured
on a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE), and the integrity of the RNA was checked on
a 1% agarose gel. Good-quality RNA samples were used for subse-
quent analysis.
Quantitative RT-PCR
MiRNA expression was measured using a prerelease version of the
TaqMan miRNA quantitative PCR assay including a total of 183
human miRNA from Applied Biosystems (Foster City, CA) as previ-
ously described [15].
Briefly, cDNA was made from 5 ng of total RNA in 15-μl re-
actions using (Multiscribe) MuLV RT and specific primers for each
miRNA. The RT reaction was performed at 16°C for 30 minutes
followed by 42°C for 30 minutes, 85°C for 5 minutes, and a final
hold at 4°C. The PCR mix consists of 1.33 μl of cDNA from the
RT product, 10 μl of Eurogentec Master Mix (Eurogentec, Liege,
Belgium), and 2 μl of TaqMan MicroRNA Assay Mix contain-
ing primers and probe for the miRNA of interest, in a total volume
of 20 μl. Cycle parameters for the PCR are 95°C for 10 minutes
(AmpliTaq Gold enzyme activation), followed by 40 cycles of a de-
naturing step at 95°C for 15 seconds and an annealing/extension step
at 60°C for 60 seconds. All reactions were run in triplicate. Mean
cycle threshold (C t) values for all miRNA were quantified with the
sequence detection system software (SDS, version 2.1; Applied Bio-
systems). The miRNA expression was normalized to U6 mRNA ex-
pression resulting in a ΔC t from which the 2
−ΔC t value was derived
and depicted.
Cluster Analysis
Unsupervised clustering analysis of C t data was performed using
Genesis [18]. After median centering of the C t data over all samples,
complete similarity metrics were calculated for these analyses. Un-
supervised clustering was performed using the Pearson correlation co-
efficient. MiRNA that were discriminative (t-test, P < .05) between
cHL cell lines and EBV-transformed CB-derived lymphoblastoid cell
lines, between cHL and PMBL cell lines, and between cHL and BL
cell lines were depicted using a heat map.
Microarray Hybridization
Microarray analysis was performed by Agilent using the Agilent
Oligo Microarray Kit (G4470A; Agilent, Santa Clara, CA) and the
protocol provided by the company [16]. Briefly, 100 ng of total
RNA, also used for qRT-PCR, was treated with calf intestine alkaline
phosphatase for 30 minutes at 37°C before labeling. Samples (7 μl)
were diluted with 5 μl of DMSO (D8418; Sigma, St. Louis, MO),
denatured for 10 minutes at 100°C and labeled in a total volume of
20 μl at 16°C for 2 hours using pCp0-Cy3 in T4 RNA ligation buf-
fer supplied in the company kit (5190-0408; Agilent). After purifica-
tion with Bio-Rad MicroBio-Spin 6 columns (732-6221; Bio-Rad,
Hercules, CA), labeled miRNA were kept on ice.
Samples were hybridized at 55°C for 20 hours in an Agilent SureHyb
chamber (G2534A; Agilent) rotated at 20 rpm. The arrays were washed
with Gene Expression Wash Buffer (Agilent) at 37°C under required
ozone conditions before scanning with an Agilent microarray scanner
(G2565BA; Agilent).
Microarray data analysis was performed using Agilent Feature Extrac-
tion Software (www.agilent.com/chem/fe) with the protocol available
for miRNA expression analysis at www.agilent.com/chem/feprotocols.
MiR-155 Target Prediction
A list of potential miR-155 targets was created by combining pre-
dicted targets from mirBase, TargetBoost, TargetScanS, miRanda,
and PicTar (reviewed by Watanabe et al. [19]). Potential targets were
chosen based on gene function, number of predicted target sites, and
target prediction by multiple algorithms and were subsequently vali-
dated using a luciferase reporter assay, as described below in detail.
MiR-155 Target Cloning
Putative miR-155 target sequences were amplified using primers,
with NotI and SstI restriction sites (Table W2). Polymerase chain re-
action products were ligated into a TOPO vector (Invitrogen, Breda,
the Netherlands) and transformed into TOP10F′ competent cells
(Invitrogen). Using NotI and SstI endonucleases (Invitrogen), the
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insert was cut out, purified, and ligated into the 3′ UTR of Renilla
luciferase (RL) in a modified psiCHECK2 vector (Promega, Madison,
WI). This vector also contains a firefly luciferase (FL) gene used to
normalize for transfection efficiency. The constructs were sequenced
to check for the proper insert.
Transfection of Hodgkin Cell Lines L428, L1236, and DEV
Using an Amaxa nucleofector device (AAD-1001; Amaxa,
Gaithersburg, MD), cell lines were transfected with 2 μg of the
modified psiCHECK2 plasmid containing a target 3′ UTR with
or without 5.7 μM anti–miR-155 LNA-modified oligonucleotides
(Custom LNA Oligonucleotides; Exiqon, Vedbaek, Denmark) in
100 μl of nucleofector solution (Amaxa) in triplicate. An additional
control using an inhibitor against miR-220 (not expressed in HL cell
lines) was performed for all putative targets. L1236 and DEV were
transfected using kit V (protocols T01 and G16); L428 was trans-
fected with kit L (protocol X01). Transfection efficiencies of living
cells were tested using a green fluorescent protein plasmid and were
39% for L1236, 51% for DEV, and 88% for L428.
Generation of Seed Sequence Mutants
Mutated seed sequences were generated using psiCHECK2 plas-
mids as a template. The 7-nt miR-155 seed regions in the AGTR1
and FGF7 constructs were deleted using the QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) as reported previously [20].
Briefly, a forward mutagenic deletion primer and a complementary re-
verse mutagenic deletion primer were synthesized for AGTR1 (for-
ward: 5′-CTTCACTACCAAATGGCTACTTTTCAGAAT-3′;
reverse: 5′-ATTCTGAAAAGTAGCCATTTGGTAGTGAAG-3′).
Mutants were generated in a PCR experiment as described by the
manufacturer. The amplified DNA was treated with DpnI restriction
enzyme to eliminate the parental template, and the remaining DNA
was used for transformation. The deletion of the miR-155 seed bind-
ing sequence was confirmed by sequencing. The seed sequence mutant
for murine FGF7 (CCTCTGTGATTACAGGAATTA) was kindly
provided by Dr. B. Mari (Faculté de Médecine Pasteur, Nice, France).
Luciferase Assay
Cell lysates were made 48 hours after transfection using the lysis
buffer provided by the Promega Dual-Luciferase Reporter Assay Sys-
tem (E1910; Promega). In a 96-well plate, 40 μl of cell lysates was
added to 100 μl of LARII (Promega) in duplicate. Firefly luciferase
was measured in duplicate using a Luminoscan Ascent plate reader
(Thermo Scientific, Waltham, MA). After the addition of 100 μl of
Stop & Glo buffer, RL activity was measured on the Luminoscan
Ascent plate reader. MiR-155 targeting was validated with an miR-
155–specific inhibitor (Exiqon) and compared to transfection with-
out an inhibitor (mock). An inhibitor against miR-220, which is not
expressed in HL cell lines, was cotransfected as a control for non-
specific effects (not shown).
In this assay, RL expression is reduced on binding of miR-155 to
the target sequences cloned into the 3′-UTR of the RL gene. Protein
expression of the RL gene was normalized to the signal obtained
from FL (endogenous transfection control) resulting in a relative
luciferase expression. The RL/FL ratio of cells cotransfected with
anti–miR-155 or anti–miR-220 (used as a negative control) was
compared to cells transfected only with the construct of interest
(set at 100%).
Statistical Analysis on Large Panel of Cell Lines
Differential expression between cell lines was established using a
nonparametric Kruskal-Wallis test in Prism 5.0 (GraphPad Software
Inc., San Diego, CA). P values <.05 were considered statistically sig-
nificant. Dunn’s multiple comparisons posttest was performed on sig-
nificantly differentially expressed miRNA to determine which group
of cell lines deviated significantly from HL. Asterisks indicate increas-
ing levels of significance.
Results
Hodgkin Lymphoma–Specific Pattern of miRNA Expression
Quantitative RT-PCR for 183 miRNA was used to define an
HL-specific pattern of miRNA expression. The 26 most abundantly
expressed miRNA within the HL cell lines (L428, L1236, HDLM2,
and KM-H2) included miR-92, miR-21, miR16, miR142-3p, mir-
17-5p, and miR-155 (Table 1). Remarkably, within the group of
26 highly expressed miRNA, an overlap in genome position and seed
sequence (seed families) was identified. Unsupervised clustering indi-
cated that cHL cell lines clustered separately from CB-LCL, PMBL,
and BL cell lines (Figures 1 and W1). The NLPHL cell line DEV
clustered more closely to CB-LCL than to HL (Figure 1A). Burkitt
lymphoma cell lines were located in a separate cluster, together with
the T-cell HL cell line HDLM2. Of a total of 23 miRNA that were
differentially expressed, 3 were found between cHL and PMBL cell
lines, 8 between cHL and CB-LCL, and 17 between cHL and BL
(Figure 1). In all three comparisons, most of the differentially ex-
pressed miRNA were upregulated in HL, including let-7e compared
with LCL and BL (P = .0004 and P = .01), miR-155 compared with
BL (P = .007), and miR-107 compared with PMBL (P = .05). Only a
few miRNA were downregulated in HL, among which was miR-150
Table 1. Abundantly Expressed miRNA in Classic Hodgkin Cell Lines.
No. miRNA Chromosome Seed Family*
1 miR-15b 3q26.1 AGCAGCA
2 miR-16 3q26.1/13q14.2 AGCAGCA
3 miR-191 3p21.31
4 miR-565 3p21.31
5 miR-103 5q35.1/20p13
6 miR-25 7q22 AUUGCAC
7 miR-93 7q22 AAAGUGC
8 miR-106b 7q22 AAAGUGC
9 miR-29a 7q32.3 AGCACCA
10 miR-29b 7q32.3/1q32.2 AGCACCA
11 miR-29c 1q32.2 AGCACCA
12 miR-30b 8q24.2
13 Let-7a 9q22.32/11q24.1/22q13.31 GAGGUAG
14 Let-7f 9q22.32 GAGGUAG
15 Let-7g 3p21.1 GAGGUAG
16 miR-17-5p 13q31 AAAGUGC
17 miR-19a 13q31 GUGCAAA
18 miR-19b 13q31 GUGCAAA
19 miR-20a 13q31 AAAGUGC
20 miR-92a 13q31/Xq26.2 AUUGCAC
21 miR142-3p 17q23.2
22 miR142-5p 17q23.2
23 miR-21 17q23.2
24 miR-155 21q21
25 miR-106a Xq26.2 AAAGUGC
26 miR-20b Xq26.2 AAAGUGC
*An miRNA family is composed of miRNA with the same seed region (positions 2 to 8 of the
mature miRNA, also called seed+m8) (http://www.targetscan.org). MiRNA are grouped by location
and seed family as indicated by altering shades of gray.
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that was significantly downregulated in HL compared with LCL (P =
.05), PMBL (P = .01), and BL (P = .02; Figure 1).
To underline these qRT-PCR data, miRNA microarrays were per-
formed for cHL, CB-LCL, and PMBL cell lines. C t values obtained
with qRT-PCR correlated well with signal intensities on the array
(0.56 ≤ r2 ≤ 0.70), indicating that the qRT-PCR data are consistent
with the Agilent miRNA microarray (Figure 2). The 26 most abun-
dant miRNA in cHL cell lines, as detected with qRT-PCR, were also
among the most abundant as detected by miRNA microarray. More-
over, the miRNA differentially expressed between cHL and CB as well
as cHL and PMBL did not deviate from the regression line, indicating
that differential expression was based on accurate quantification.
Hodgkin Lymphoma–Specific miRNA Signature on Extended
Cell Line Panel
Of the 23 differentially expressed miRNA (Figure 1), we selected
let-7e, miR-9, miR-23a, miR-24, miR-27a, miR-98, miR-100, miR-
107, miR-125a, miR-130b, miR-150, miR-153, miR-155, miR-181a,
miR-206, and miR-342 for further analysis. These 16 miRNA and 22
of the 26 highly expressed miRNA in HL cell lines (Table 1) were
compared on an extended cell line panel, including EBV-transformed
LCLs, BL cell lines, PMBL cell lines, DLBCL, and lymphocytic
leukemia cell lines (CLL). Of the selected 16 differentially expressed
miRNA, 8 were significantly different between HL and other cell lines,
whereas of the 22 highly expressed miRNA, 19 miRNA significantly
differed in expression levels (Figure 3). There was no differential ex-
pression of miR-155, miR-181a, miR-98 (HL vs BL), miR-107, miR-
150 (HL vs PMBL), miR-342, miR-150, and miR-100 (HL vs LCL)
in this larger cell line panel. For miR-155, high levels were found in
the EBV-positive CLL and LCL cell lines, indicating a positive relation
between EBV positivity and miR-155 expression. Hodgkin lymphoma
cell lines significantly overexpressed a large number of well-known
miRNA, including miR-21, miR-15b, and miR-16. Furthermore,
there was a strong up-regulation of miR-17-92 cluster members,
Figure 1. Characterization of cell lines based on differential miRNA expression patterns. The Euclidian distance between cell lines and
miRNA based on miRNA expression as found by an unsupervised hierarchical clustering (A). Differentially expressed miRNA identified
by a t-test between cHL and PMBL (B), between cHL and CB-LCL (C), and between cHL and BL (D).
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Figure 2. Correlation between miRNA microarray and qRT-PCR expression levels. The miRNA microarray contained 170/183 miRNA
tested by qRT-PCR. Low C t values (x-axis), obtained by qRT-PCR, correlate with high signal intensity (y-axis) observed with microarray.
The high correlation coefficient (r2) indicates a positive relation between low C t values and high signal intensity. Both platforms show the
same miRNA abundantly expressed in HL (open triangles). MiRNA differentially expressed between cHL and CB and cHL and PMBL
(open squares) do not deviate from this correlation. For some miRNA, no expression was observed by qRT-PCR (C t value of 40), whereas
low/average expression was observed on the microarray.
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Figure 3. Differential expression of selected miRNA in a large panel of cell lines. Abundant miRNA (A) and differentially expressed miRNA
(B) selected from qRT-PCR profiling were evaluated on a panel of lymphoma cell lines. MiR-155, shown in (B), was both highly and dif-
ferentially expressed in the initial profile. In (B), HL cell lines with a significantly higher miRNA expression in the initial screen on differential
expression (Figure 1) are marked in red, whereas cell lines that contained a significantly lower expression of the given miRNA are marked in
blue. Data for miR-206 and miR-153 were not shown because their expression was too low (C t values >35) to be quantified reliably.
Significant differences in a comparison between all groups were obtained by a Kruskal-Wallis test and are marked with asterisks next
to the miRNA name. Asterisks within the plots indicate significant differences between Hodgkin cell lines and other categories specifically
as found by Dunn’s multiple comparison test. For both tests: *P < .05, **P < .01, and ***P < .001.
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compared to BL (miR-19a, miR-19b, and miR-20a), DLBCL (miR-
19b), LCL (miR-92), and CLL (miR-19a, miR-20a, and miR-92;
Figure 3). Also, analogous cluster members located at chromosome
Xq26 (miR-106a) and chromosome 7q22 (miR-25, miR-93, and
miR-106b) were highly expressed in HL (Table 1). MiR-17-5p
showed a trend for higher expression in HL (Figure 3A), whereas
miR-18a was not differentially expressed and miR-17-3p showed sig-
nificantly lower expression in HL compared to DLBCL cell lines. The
most significant differences were generally found between HL and BL.
No significant differences were found between HL and PMBL.
MiR-155 Target Gene Validation
On the basis of the abundant and differential expression of miR-
155 in HL and the reported interest for miR-155, both by our group
and other groups, we chose to further validate putative target genes of
miR-155. Putative target genes identified by one or more of five dif-
ferent target prediction algorithms (PicTar, TargetBoost, TargetScanS,
MiRanda, and miRbase) were screened for the location and number of
putative binding sites as well as their biologic relevance. Eleven puta-
tive targets were selected, cloned into the 3′ UTR of an RL reporter
gene of a modified psiCHECK2 vector containing and transfected into
HL cell lines L428, L1236, and DEV for further target validation
(Figure W2). Selection of these cell lines was based on differences in
miR-155 levels as previously demonstrated by Northern blot analysis
[12]. Using qRT-PCR, we showed that miR-155 levels are high in
DEV and L1236 and relatively low in L428 (Figure 4). After cotrans-
fection with anti–miR-155 oligonucleotides, significantly increased rel-
ative luciferase expression levels were obtained for AGTR1, ZNF537
(TSHZ3), FGF7 (KGF), ZIC3,MAF, and IKBKE, implying that these
genes are true miR-155 targets (Figure 5). The RL/FL ratios did not
coincide with the level of repression observed after the addition of
anti–miR-155 oligonucleotides, indicating that the ratio itself is not
a good measure for the extent of miRNA-based repression (Fig-
ure W3). Cotransfection with oligonucleotides against miR-220, a
miRNA that is not expressed in the HL cell lines, did not alter lucif-
erase expression (data not shown). Moreover, transfection with AGTR1
Figure 3. (continued)
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and FGF7, containing mutated seed sequences, confirmed the effects
obtained by the anti–miR-155 oligonucleotides (data not shown).
Discussion
MicroRNA profiling has been used to classify human cancers ac-
cording to their developmental lineage and differentiation state [21].
In lymphoid malignancies, miRNA profiles have been used to suc-
cessfully characterize BL and CLL [22,23]. In addition, Navarro et al.
[24] have used miRNA profiling on total HL tissue specimens to
distinguish between different HL subtypes, and Nie et al. [25] have
shown that Blimp-1 is a target of miR-9 and let-7a in HL cell lines.
Up until now, no studies have reported on a complete miRNA ex-
pression profile for HRS cells of HL.
In this study, we compared the miRNA expression profile of HL
to that of other B-cell–derived lymphoma cell lines using qRT-PCR
and miRNA microarrays to screen 183 and 470 different human
microRNA, respectively. The results obtained from these indepen-
dent platforms were significantly correlated, and verification on a
large panel of B-cell–derived cell lines revealed that 19 of 22 selected
highly expressed miRNA were consistent and that 8 of 16 selected
differentially expressed miRNA were differentially expressed between
HL and a large panel of other B-cell lymphoma–derived cell lines
(Figure 3). The lack of differential expression for 8 of the miRNA
is most likely caused by the heterogeneity in miRNA profile of the
HL cell lines used in the larger cell line panel (including the non-
cHL cell line, DEV, the T-cell–derived HL cell line, HDLM2, and
the EBV-positive HL cell line, L591). The differences in miRNA
profiles can be seen for two of these cell lines in Figure 1A. Although
half of the selected miRNA within the larger panel were not signifi-
cantly differentially expressed, consistent results were obtained for the
three cHL cell lines used to identify differentially expressed miRNA.
Compared to other B-cell lymphoma cell lines, overexpression of
the miR-17-92 cluster members miR-17-5p, miR-19a, miR-19b,
miR-20a, and miR-92, is prominent in HL. Furthermore, a high
expression of analogous cluster members miR-106a, miR-25, and
miR-93, derived from chromosome 7 and X, implies an important role
of these clusters of miRNA with partially overlapping seed sequences
in the pathophysiology of HL [26]. Although most miR-17-92 cluster
members (but not miR-17-3p and miR-18a) are highly expressed in
HL, we show that differences in expression levels between miRNA
derived from this single cluster exist. This implies not only that expres-
sion depends on the primary transcript levels but also that some cluster
members are more or less stable or specifically regulated, as has previ-
ously been shown for pre–miR-18a [27]. Moreover, highly expressed
Figure 4. Quantitative RT-PCR on miR-155 expression in HL cell
lines. Triplicate measurements were performed for three (two for
L1236) separate RNA isolations. Constant miR-155 levels were ob-
served for cells that were harvested at different time points.
Figure 5. Relative luciferase expression after miR-155–specific inhibition was indexed relative to the ratio obtained without inhibitor.
Relative luciferase ratios are given for the cell lines transfected with psiCHECK2 constructs containing 3′ UTR sequences of potential
miR-155 target genes. Error bars indicate the SD for three replicate experiments. AGTR1 (DEV), ZNF537 (DEV, L1236), FGF7 (DEV,
L1236), ZIC3 (DEV), MAF (L1236), and IKBKE (L1236) show increased expression after miR-155–specific inhibition.
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miRNA were not specifically located within aberrant chromosomal re-
gions, present in the tested HL cell lines [28,29].
MiR-15 and miR-16 are both abundantly and differentially ex-
pressed in HL. Reduced levels of both these miRNA, which are known
to target BCL2, have been shown to protect cells against apoptosis in
CLL [30]. High Bcl-2 protein levels in HRS cells have been reported as
a marker for unfavorable prognosis in HL cases [31]. Because not only
Bcl-2 but also miR-15 and miR-16 expression levels are high in HL,
miR-15– and miR-16–mediated repression of BCL2 does not seem to
occur in HL. Whereas elevated levels of miR-15 and miR-16 decrease
Bcl-2 expression, elevated levels of miR-21 have been associated with
increased Bcl-2 protein levels in breast cancer cell lines [32]. If BCL2
is indeed a target of both miR-21 and miR-15/-16 in HL, high miR-21
expression might, presumably indirectly, counteract repression of BCL2
translation, induced by miR-15 and miR-16.
Although most miRNA had significantly higher expression levels
in HL compared to other B-cell lymphoma cell lines, the level of
miR-150 expression was significantly lower. MiR-150 is expressed
in mature B and T cells and it has been shown to target the transcrip-
tion factor c-Myb [8,33]. In our cell line panel, the only HL with
abundant miR-150 levels was HDLM2, a T-cell–derived HL cell
line. We found the largest difference in miR-150 expression levels
between HL and CLL cell lines. In CLL, we previously reported that
miR-150 expression levels were strong and homogeneous for neo-
plastic cells outside proliferation centers and absent or very low for
the CLL cells in the proliferation centers, and this staining pattern
was inversely correlated to miR-155 expression levels [34].
In HL cell lines and cases, the primary miR-155 gene BIC and miR-
155 are abundantly expressed [12], whereas in BL, BIC and miR-155
expression are almost absent [13]. The lack of significant differences
for miR-155 between HL and BL cell lines is probably caused by in-
clusion of the three EBV-positive BL cell lines Jiyoye, Namalwa, and
Raji, which express high levels of miR-155. We have previously re-
ported on the putative relation between latency type III EBV-
positive BL cell lines and miR-155 expression [13]. In line with this
and consistent with observations by others [35], the EBV-transformed
LCL cell lines used in our study were also miR-155–positive.
Previously, AGTR1 [20,36], IKBKE [36,37], BACH1 [36,38], Fos
[36], Pu.1 [39], ZIC3 [38], and TP53INP1 [40] were shown to be
miR-155 target genes in various cell lines. We demonstrate effective
targeting in HL by miR-155 for AGTR1, IKBKE, ZNF537, ZIC3,
and FGF7. Remarkably, the extent of target inhibition in the HL cell
lines seemed to correlate with the miR-155 levels. We show that
miR-155–mediated repression of these miR-155 target genes in
HL cell lines depends on the cellular context and possibly the
amount of available miRNA (Figures 4 and 5). This has been sug-
gested previously for miR-150 by Xiao et al. [33] who have shown
that small changes in miR-150 expression profoundly affects the ex-
pression of its target gene c-Myb in hematopoietic cell lineages spe-
cifically. On the basis of conditional and partial ablation of c-Myb,
effective repression of c-Myb by miR-150 is determined within a
narrow window of expression of both miR-150 and c-Myb [33].
The lack of luciferase suppression, as observed in the miR-155-low
cell line L428 (which has the best transfection efficiency), might be
due to low levels of miR-155 or to repression by miRNA other than
miR-155. Differences in repression between DEV and L1236, both
with high levels of miR-155, indicate that it is important to study
miRNA function in cell lines with relevant endogenous miRNA ex-
pression levels and not in cell lines of other cell types.
IKBKE (IKKɛ)-mediated phosphorylation of cRel leads to dissocia-
tion of the IκBα-cRel complex resulting in nuclear accumulation of
cRel and subsequent NF-κB activation [41]. In HL, cREL is often
amplified [42] resulting in the activation of NF-κB. The high levels
of miR-155 in HL cell lines might represent a counter action to reduce
activated NF-κB levels [37]. This is supported by our observation on
cREL amplification without increased mRNA levels in HL cell lines
[28]. The angiotensin type II receptor 1 (AGTR1/AT1) is expressed
on B cells and monocytes [43]. Recently, a single nucleotide polymor-
phism in the 3′ UTR of AGTR1 (A1166C) has been shown to affect
miR-155–mediated repression [44]. ZNF537 (TSHZ3) is a highly
conserved human variant of the teashirt (tsh) gene. TSHZ3 might
act as a transcriptional repressor, which in Drosophila can be activated
by FGF8 [45]. The potential miR-155 target gene FGF7 (KGF ) is a
canonical fibroblast growth factor family member known to activate
Akt [46]. In HL, Akt is activated, possibly through CD40, CD30,
and RANK [47]. However, there is no data on the expression and
function of AGTR1, TSH23, ZIC3, and FGF7 in HRS cells. Expres-
sion of MAF has only been detected on the mRNA level in HL cell
lines L1236 and KM-H2, whereas no protein expression was found by
immunohistochemistry in HL patients [48].
We conclude that HL is characterized by high expression levels of
various miRNA. The miRNA expression profile of HL cell lines can
be used to distinguish HL from other B-cell–derived cell lines be-
cause HL cell lines cluster separately based on miRNA expression.
We also show that IKBKE, ZNF537, ZIC3, FGF7, and AGTR1
are functional targets of miR-155 in HL.
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Table W2. Primer Sequences Used for Amplification of Target Sequences.
Gene Forward Primer* (5′–3′) Reverse Primer† (5′–3′) Size (bp)
GAB2 GAGCTC-ATGTCAGATCGCAGGGTAGG TCTAGA-AGTCGCTCTCCGAAGATTCC 1205
BACH2 GAGCTC-GGAAAGACAGCAGTGATGAC GCGGCCGC-GTGCAAGTGGCAAAGTTGAC 659
ICOSL GAGCTC-AGGGCCGTGTTTGGCTACAG TCTAGA-CCTCAGGCATGAGGGACAGA 1187
ZIC3 GAGCTC-TGGTACGTCTGAGGACAAAC GCGGCCGC-GAGTCTTCCCAGATGGAAAC 979
IKBKE GAGCTC-TCCCAGCACCTCCTGATGTC GCGGCCGC-CTGCTTCCCAGGGAGAAAGG 215
TIP120 TGTTTGGCTTTCTTCCATTG AGAAAGAAATTCATGGTCAC 226
AGTR1 GAGCTC-CATGTTCGAAACCTGTCCATAAAG GCGGCCGC-ATAAAATTATTTTATTTTAAAGTAAAT 897
ZNF537 GAGCTC-TGTGGAAGGCACCTTCAG TCTAGA-CCAGCTCCGTCATAAACAG 1668
FGF7 ACTACTCGAGCTGATCAAGCTGGACTTGCGC ATAAGAATGCGGCCGCTAACAAAACAATAAAATTCAAATACAAC 790
MNAB TTGTGACCACACCATGGAAG TTACTGCACCGGATTGCTAC 282
MAF GAGCTC-AAGCCTGCATCAACCTTCTG GCGGCCGC-GGGCAATTATGGCTCAACTC 1795
TIP120, MNAB, and FGF7 were subcloned first in a TOPO vector and lack specific restriction sites. Size indicates the size of the PCR product that was cloned into the vector.
*The restriction site for endonucleases NotI was added to the forward primer.
†The restriction site for SstI or XbaI was added to the reverse primer (separated by dash).
Table W1. Cell Lines Used for miRNA Expression Validation.
Class Name EBV Reference
HL L428 (cHL) − [1,2]
KM-H2 (cHL) − [2]
HDLM2 (T-cell HL) − [2]
L1236 (cHL) − [2,3]
L591 (cHL) + [2]
DEV (NLPHL) − [4,5]
PMBL MedB-1 − [6]
Karpas 1106P − [6]
DLBCL ROSE − [2]
VER − [2]
SU-DHL-4 − A. Epstein (UCLA)
SU-DHL-6 − A. Epstein (UCLA)
OCI Ly3 − [7]
SCHI −
BL Raji + [8]
CA46 − [8]
BL-65 + [8]
Namalwa + [8]
DG-75 − [8]
Jiyoye + [8]
Ramos (RA 1) − [8]
LCL CB-LCL 6.28 + [9]
CB-LCL 5.5-1 + [9]
CB-LCL 5.b2 + [9]
CB-LCL 6.16 + [9]
CB-LCL 5.B8 + [9]
1H2 (EBV transformed) + [10]
15E6 (EBV transformed) + [10]
CLL EHEB (B-CLL) + DSMZ
MEC-1 (B-CLL) + DSMZ
MEC-2 (B-CLL) + DSMZ
JVM-3 (B-CLL) + DSMZ
DSMZ=Deutsche Sammlung vonMicroorganismen unZellkulturen,GmbH, located in Braunschweig,
Germany.
FigureW1. Heat chart of miRNA expression in B-cell–derived cell lines.
Figure W2. Schematic presentation of the predicted target sequences cloned in the psiCHECK2 vector. The regions from the 3′ UTR of
potential miR-155 targets (A) were cloned into psiCHECK2 vector (B) for target gene validation experiments.
Figure W3. The FL/RL luciferase expression ratios observed in the
three HL cell lines without miR-155–specific inhibitor. Luciferase
ratios obtained for the psiCHECK2 constructs containing 3′ UTR
sequences of potential miR-155 target genes. Error bars indicate
the SD for three replicate experiments.
